Orlistat, an under-recognised cause of progressive renal impairment

Obesity is an emerging risk factor for chronic kidney disease (CKD) in the developed world. Orlistat, an intestinal lipase inhibitor, used in the treatment of obesity is available as an over-the-counter medication across the European union and in many countries worldwide. It is associated with acute...

Full description

Saved in:
Bibliographic Details
Published in:Nephrology, dialysis, transplantation dialysis, transplantation, 2013-11, Vol.28 Suppl 4 (suppl 4), p.iv172-iv174
Main Authors: Coutinho, Andrew K, Glancey, Gerald R
Format: Article
Language:English
Subjects:
Acute Kidney Injury - chemically induced
Acute Kidney Injury - diagnosis
Aged
Anti-Obesity Agents - adverse effects
Diabetes Mellitus, Type 2 - complications
Disease Progression
Essential Hypertension
Female
Humans
Hypertension - complications
Lactones - adverse effects
Lipase - antagonists & inhibitors
Male
Middle Aged
Obesity - drug therapy
Orlistat
Prognosis
Risk Factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Obesity is an emerging risk factor for chronic kidney disease (CKD) in the developed world. Orlistat, an intestinal lipase inhibitor, used in the treatment of obesity is available as an over-the-counter medication across the European union and in many countries worldwide. It is associated with acute kidney injury (AKI). We present three adults, followed up from 1 to 6 years, who developed de novo or worsening renal impairment while on orlistat. Stopping the drug halted progression, but did not reverse the degree of renal impairment at presentation.
ISSN:0931-0509
1460-2385
DOI:10.1093/ndt/gft066